In a view of recent findings linking leptin signalling to the sphingolipid pathway it may be reasonable to investigate this link in prostate cancer, specifically in a view of developing new chemo- or radio-sensitizing therapies. The gene discussed is LEP; the disease is prostate carcinoma.